Jaguar Animal Health (NASDAQ:JAGX – Get Free Report) and Dare Bioscience (NASDAQ:DARE – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk and analyst recommendations.
Insider & Institutional Ownership
12.0% of Jaguar Animal Health shares are held by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are held by institutional investors. 0.1% of Jaguar Animal Health shares are held by company insiders. Comparatively, 3.4% of Dare Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Jaguar Animal Health and Dare Bioscience, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Jaguar Animal Health | 1 | 0 | 0 | 0 | 1.00 |
| Dare Bioscience | 1 | 0 | 3 | 0 | 2.50 |
Volatility & Risk
Jaguar Animal Health has a beta of -0.09, suggesting that its stock price is 109% less volatile than the S&P 500. Comparatively, Dare Bioscience has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500.
Profitability
This table compares Jaguar Animal Health and Dare Bioscience’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Jaguar Animal Health | -179.03% | N/A | -136.47% |
| Dare Bioscience | -748.97% | -790.40% | -40.40% |
Earnings and Valuation
This table compares Jaguar Animal Health and Dare Bioscience”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Jaguar Animal Health | $27.79 million | 0.02 | -$53.43 million | ($3,731.34) | -0.00 |
| Dare Bioscience | $1.03 million | 8.63 | -$13.40 million | ($0.70) | -0.65 |
Dare Bioscience has lower revenue, but higher earnings than Jaguar Animal Health. Dare Bioscience is trading at a lower price-to-earnings ratio than Jaguar Animal Health, indicating that it is currently the more affordable of the two stocks.
Summary
Dare Bioscience beats Jaguar Animal Health on 9 of the 13 factors compared between the two stocks.
About Jaguar Animal Health
Jaguar Health, Inc., formerly Jaguar Animal Health, develops prescription medicines for gastrointestinal disorders in humans and animals. The company’s research has focused on plant-derived compounds, including crofelemer, which is derived from the Croton lechleri tree. Jaguar’s animal-health product Canalevia-CA1 received FDA conditional approval for the treatment of chemotherapy-induced diarrhea in dogs. The company also develops and commercializes crofelemer-based medicines for human gastrointestinal conditions.
About Dare Bioscience
Daré Bioscience is a clinical-stage biopharmaceutical company focused on developing therapies and products for women’s health. Its work spans areas including contraception, vaginal health and sexual health, with an emphasis on addressing conditions and needs that have had limited treatment options. The company’s product candidates include Ovaprene, a hormone-free, monthly-use vaginal contraceptive, and investigational treatments for conditions such as female sexual arousal disorder. These candidates remain in development and are not approved for general use.
Receive News & Ratings for Jaguar Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
